PCN100 Economic Burden in Patients with Metastatic Cervical Cancer: A Truven MarketScan Database Study

Zhang, Y.; Batech, Michael; Lamy, François-Xavier; Pan, Xiaotian

doi:10.1016/j.jval.2021.04.192

Cited by 2 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We performed a retrospective cohort study using integrated data from five medical claims data sets, with data from January 1, 2012, to December 31, 2017. The data sources included (1) the US Centers for Medicare & Medicaid Services (CMS) Medicare (fee‐for‐service); (2) IBM (formerly Truven) MarketScan® Commercial Claims and Encounter Database 13 ; (3) IQVIA PharMetrics Plus™ 14 ; (4) Optum Clinformatics™ Data Mart 15 ; and (5) Humana Research Database 16 . The five integrated data sets were chosen for completeness, size, and complementary population heterogeneity—with precedent for our methodology 17,18 .…”

Section: Methodsmentioning

confidence: 99%

Contemporary prevalence estimates of undiagnosed and diagnosed atrial fibrillation in the United States

Turakhia

Guo

Keshishian

et al. 2023

Clinical Cardiology

View full text Add to dashboard Cite

Background Atrial fibrillation (AF) prevalence estimates vary and have been based on cohorts with clinically established or diagnosed disease. Undiagnosed AF prevalence estimates are less certain as they are based on nongeneralizable convenience samples. Hypothesis Because AF is often asymptomatic, it my remain undiagnosed until the development of complications such as stroke or heart failure. Consequently, the observed prevalence of diagnosed AF from the literature may underestimate total disease burden. We therefore sought to estimate the total prevalence of both diagnosed and undiagnosed AF. Methods We performed a retrospective cohort study from 2012 to 2017 using data from five US medical claims data sets. Undiagnosed AF prevalence was estimated based on the observed incidence of ischemic stroke, systemic embolism (SE), and AF incidence after a stroke/SE. The diagnosed AF cohort included AF patients between Q1 2014 and Q3 2015. The undiagnosed AF cohort were patients with assumed undiagnosed AF in the year before a stroke/SE and who were newly diagnosed with AF in the 3‐month poststroke/SE. Stroke/SE incidence was calculated among all AF patients and the ratio of number of undiagnosed AF patients to stroke rate was created. Age‐ and sex‐adjusted estimates were stratified by period of assumed undiagnosed AF before poststroke/SE AF diagnosis (1 or 2 years). Results The estimated US prevalence of AF (diagnosed and undiagnosed) in Q3 2015 was 5 628 000 cases, of which 591 000 cases (11%) were undiagnosed. The assumed 2‐year undiagnosed AF prevalence was 23% (1 531 000) of the total prevalent patients with AF (6 568 000). Undiagnosed (vs. diagnosed) AF patients were older and had higher CHA2DS2‐VASc scores. Of undiagnosed AF, 93% had CHA2DS2‐VASc ≥2 and met OAC criteria. Conclusions These contemporary estimates demonstrate the high prevalence of undiagnosed AF in the United States. Undiagnosed AF patients are composed of primarily elderly individuals who if diagnosed, would meet criteria for stroke prevention therapy.

show abstract

Section: Methodsmentioning

confidence: 99%

Contemporary prevalence estimates of undiagnosed and diagnosed atrial fibrillation in the United States

Turakhia

Guo

Keshishian

et al. 2023

Clinical Cardiology

View full text Add to dashboard Cite

show abstract

“…We used data from the Truven Health Analytics MarketScan database, a private sector health data resource that reflects the health care experience of enrollees covered by the health benefit programs for employers. Data are collected from more than 100 different health insurance companies and are nationally representative of commercially insured enrollees and their dependents as well as Medicare-eligible beneficiaries with employer-provided Medicare supplemental plans.…”

Section: Methodsmentioning

confidence: 99%